NEW YORK, NY (November 15, 2017) – Too little is discussed and yet to be known about the many links between diabetes and cardiovascular disease, which is the #1 cause of morbidity and mortality in people with type 2 diabetes globally. To recognize World Diabetes Day yesterday, the nation’s leading medical societies, patient advocacy organizations and health care leaders came together to share ideas on raising awareness of the rapid rise in diabetes and the corresponding increase in cardiovascular disease, and the need to collaborate in ways that can improve care and patient outcomes.
Hosted by the Danish Ministry of Foreign Affairs, the American Diabetes Association, the American Heart Association and Novo Nordisk, a global leader in the fight against diabetes, national thought leaders met at the Danish Consulate in New York City to discuss:
- Key risks driving cardiovascular disease among patients with type 2 diabetes;
- The latest trends in cardiovascular care that can improve patient outcomes; and
- Current leadership activities to increase the dialogue and investigation about cardiovascular disease and type 2 diabetes.
“We can’t have this discussion enough knowing that people with type 2 diabetes have an increased risk of dying from a cardiovascular event,” said Todd Hobbs, MD, US chief medical officer for Novo Nordisk. “There have been many advances in the management of CV risk factors that have reduced the rate of cardiovascular events. However, residual CV risk remains a significant concern for the specialists treating these patients and we need to find innovative ways to reach them.”
“The more we understand the links between diabetes and cardiovascular disease, the more we can collaborate on ways to improve the lives of millions of people. As a medical community, we must take urgent action to reduce mortality, and together, we can bring about meaningful change in this regard,” said the ADA’s Chief Scientific, Medical and Mission Officer William T. Cefalu, MD.
“Better understanding the connection between diabetes and cardiovascular disease is critical to improving patient outcomes and quality of life,” said Eduardo Sanchez, M.D., M.P.H. FAAFP, American Heart Association Chief Medical Officer for Prevention and Chief of the Center for Health Metrics and Evaluation. “The American Heart Association, the world’s leading voluntary health organization devoted to optimizing cardiovascular health, is bringing our knowledge and experience in prevention and treatment to improve patient care for people with heart disease, prediabetes, and type 2 diabetes.”
About Novo Nordisk
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: hemophilia, growth disorders and obesity. With U.S. headquarters in Plainsboro, N.J., Novo Nordisk Inc. has nearly 5,000 employees in the United States. For more information, visit novonordisk.us or follow us on Twitter: @novonordiskus.